Abstract

BackgroundSince December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel etiologic agent of viral pneumonia. We aimed to compare clinical features of 165 Italian patients with laboratory confirmed or unconfirmed 2019-nCoV pneumonia.MethodsOn March 31, 2020, hospitalized patients who presented with fever and/or respiratory symptoms, exposures, and presence of lung imaging features consistent with 2019-nCoV pneumonia were included. Before admission to a hospital ward, patients underwent RT-PCR based SARS-CoV-2 RNA detection in their nasopharyngeal swab samples.ResultsOf 165 patients studied, 119 had positive RT-PCR results and 46 were RT-PCR negative for 2 days or longer (i.e., when the last swab sample was obtained). The median age was 70 years (IQR, 58–78), and 123 (74.6%) of 165 patients had at least one comorbidity. The majority of patients (101/165, 61.2%) had a mild pneumonia, and the remaining patients (64/165, 38.8%) a severe/critical pneumonia. We did not find any substantial difference in symptoms, incubation periods, and radiographic/CT abnormalities as well as in many of the biological abnormalities recorded. However, at multivariable analysis, higher concentrations of hemoglobin (OR, 1.34; 95% CI, 1.11–1.65; P = 0.003) and lower counts of leukocytes (OR, 0.81; 95% CI, 0.72–0.90; P < 0.001) were statistically associated with confirmed COVID-19 diagnosis. While mortality rates were similar, patients with confirmed diagnosis were more likely to receive antivirals (95% vs 19.6%, P < 0.001) and to develop ARDS (63% vs 37%, P = 0.003) than those with unconfirmed COVID-19 diagnosis.ConclusionsOur findings suggest that unconfirmed 2019-nCoV pneumonia cases may be actually COVID-19 cases and that clinicians should be cautious when managing patients with presentations compatible with COVID-19.

Highlights

  • Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel etiologic agent of viral pneumonia

  • Because of substantial pneumonia-related morbidity and mortality [3], testing for SARS-CoV-2 infection of patients who meet the suspected-case definition for COVID-19 [4] is central for their management

  • We comparatively explored the clinical features of 165 patients with laboratory confirmed or unconfirmed 2019-nCoV pneumonia admitted to COVID-19 wards of the Fondazione Policlinico A

Read more

Summary

Introduction

Since December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel etiologic agent of viral pneumonia. We aimed to compare clinical features of 165 Italian patients with laboratory confirmed or unconfirmed 2019-nCoV pneumonia. The 2019 novel coronavirus (2019-nCoV), named severe acute respiratory syndrome coronavirus 2 (SARS-CoV2), became notorious since December 2019 as a new etiologic agent of viral pneumonia [1]. Real-time reverse-transcriptase–polymerase-chain-reaction (RT-PCR) based SARS-CoV-2 RNA detection in respiratory samples (e.g., nasopharyngeal swabs) is the reference diagnostic method to confirm COVID-19 [6]. We comparatively explored the clinical features of 165 patients with laboratory confirmed or unconfirmed 2019-nCoV pneumonia admitted to COVID-19 wards of the Fondazione Policlinico A. We investigated the prospect that cases with a negative RT-PCR test result are cases of 2019-nCoV pneumonia or, in other words, are not to distinguish from those without confirmation test performed

Objectives
Methods
Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.